医薬品有力企業シリーズ: 眼薬メーカー上位25社分析2016-2026...市場調査レポートについてご紹介

【英文タイトル】Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2016-2026
3.1 The World Ophthalmic Drugs Market in 2015
3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026
3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026
3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.6 How Will Market Shares Change to 2026?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2016-2026
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2016?
4.1.1.2 Restasis: Sales Forecast 2016-2026
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026
4.1.1.8 Acular: New Forms Receiving FDA Approvals
4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2016-2026
4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.3.1.2 Eylea: US Sales Forecast 2016-2026
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2016-2026
4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
4.4.2 Akorn: Revenue Forecast 2016-2026
4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026
4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2016-2026
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2016-2026
5.1.3 Bayer: Revenue Forecast 2016-2026
5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Still a Leading Drug in AMD
5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2016-2026
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2016-2026
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2016-2026
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2016-2026
5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
5.3.1.3 Avastin: Sales Forecast 2016-2026
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2016-2026
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026
5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2016-2026
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2016-2026
6.1.1.2 Hyalein
6.1.1.3 Hyalein: Sales Forecast 2016-2026
6.1.1.4 Cosopt: Non-US Sales Forecast 2016-2026
6.1.1.5 Tapros/Taflotan: Sales Forecast 2016-2026
6.1.1.6 Diquas: Sales Forecast 2016-2026
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2016-2026
6.1.1.9 Alesion: Sales Forecast 2016-2026
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2016-2026
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2016-2026
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2016-2026
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2016-2026
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
6.3.1.2 Lotemax: Sales Forecast 2016-2026
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (Latanoprostene Bunod)
6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2016-2026
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2016-2026
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt

7. Emerging Ophthalmic Drug Manufacturers in 2016
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]

9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2015
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2016-2026
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

10. Glossary


【レポート販売概要】

■ タイトル:医薬品有力企業シリーズ: 眼薬メーカー上位25社分析2016-2026
■ 英文:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
■ 発行日:2016年5月
■ 調査会社:visiongain
■ 商品コード:VGAIN60620
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。